Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Medical Informatics

Date Submitted: Feb 6, 2025
Date Accepted: Apr 28, 2025

The final, peer-reviewed published version of this preprint can be found here:

Prediction of Insulin Resistance in Nondiabetic Population Using LightGBM and Cohort Validation of Its Clinical Value: Cross-Sectional and Retrospective Cohort Study

Peng T, Miao R, Xiong H, Lin Y, Fan D, Ren J, Wang J, Li Y, Jianwen C

Prediction of Insulin Resistance in Nondiabetic Population Using LightGBM and Cohort Validation of Its Clinical Value: Cross-Sectional and Retrospective Cohort Study

JMIR Med Inform 2025;13:e72238

DOI: 10.2196/72238

PMID: 40512995

PMCID: 12180673

Prediction of Insulin Resistance in Non-Diabetic Population Using LightGBM and Cohort Validation of Its Clinical Value:: A Cross-Sectional and Retrospective Cohort Study

  • Ting Peng; 
  • Rujia Miao; 
  • Hao Xiong; 
  • Yanhui Lin; 
  • Duzhen Fan; 
  • Jiayi Ren; 
  • Jiangang Wang; 
  • Yuan Li; 
  • Chen Jianwen

ABSTRACT

Background:

Insulin resistance (IR) is central to diabetes pathogenesis and a risk factor for chronic diseases.

Objective:

This study aims to develop and validate a machine learning (ML) prediction model for IR in a non-diabetic population, using low-cost diagnostic indicators and questionnaire surveys.

Methods:

This retrospective study analyzed data from individuals who underwent physical exams and completed surveys at the Health Management Center of Xiangya Third Hospital, Central South University, from January 2018 to August 2022. Insulin sensitivity was assessed using the HOMA-IR method. A total of 17,287 non-diabetic participants aged 18 and above were included for model training with 90 features. Five ML algorithms—Random Forest (RF), LightGBM, XGBoost, GBDT, and CatBoost—were used. Model optimization included resampling, feature selection, and hyperparameter tuning. Performance was evaluated using F1 score, accuracy, sensitivity, specificity, area under the curve (AUC), and Kappa value. SHAP analysis was applied to assess feature importance. A retrospective cohort followed for five years was used for time-to-event analysis with Kaplan-Meier survival curves to validate the model’s ability to predict diabetes incidence.

Results:

Data from 16,411 non-diabetic individuals were analyzed. The dataset was split 80% for training and 20% for testing. The final model included 34 lifestyle-related questionnaire features and 17 biochemical markers. The LightGBM model showed the best IR prediction performance with an accuracy of 0.7542, sensitivity of 0.6639, specificity of 0.7642, F1 score of 0.6748, Kappa value of 0.3741, and AUC of 0.8456. In the cohort, the high-risk IR group exhibited a significantly higher 5-year cumulative incidence of diabetes.

Conclusions:

The LightGBM model effectively predicts IR status in non-diabetic individuals and identifies those at high risk of progressing to diabetes, supporting its clinical utility.


 Citation

Please cite as:

Peng T, Miao R, Xiong H, Lin Y, Fan D, Ren J, Wang J, Li Y, Jianwen C

Prediction of Insulin Resistance in Nondiabetic Population Using LightGBM and Cohort Validation of Its Clinical Value: Cross-Sectional and Retrospective Cohort Study

JMIR Med Inform 2025;13:e72238

DOI: 10.2196/72238

PMID: 40512995

PMCID: 12180673

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.